AstraZeneca PLC (NASDAQ:AZN) Shares Bought by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC raised its holdings in AstraZeneca PLC (NASDAQ:AZNFree Report) by 196.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 48,641 shares of the company’s stock after purchasing an additional 32,254 shares during the period. Tower Research Capital LLC TRC’s holdings in AstraZeneca were worth $3,276,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Anchor Investment Management LLC acquired a new stake in shares of AstraZeneca during the 4th quarter valued at approximately $26,000. Compagnie Lombard Odier SCmA acquired a new stake in AstraZeneca in the fourth quarter worth $27,000. Nemes Rush Group LLC increased its position in AstraZeneca by 375.6% in the third quarter. Nemes Rush Group LLC now owns 428 shares of the company’s stock worth $29,000 after buying an additional 338 shares during the period. Jones Financial Companies Lllp increased its position in AstraZeneca by 86.7% in the fourth quarter. Jones Financial Companies Lllp now owns 506 shares of the company’s stock worth $34,000 after buying an additional 235 shares during the period. Finally, Northwest Financial Advisors acquired a new stake in AstraZeneca in the fourth quarter worth $34,000. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Trading Down 1.0 %

Shares of AZN stock opened at $80.02 on Friday. The stock has a 50-day simple moving average of $74.21 and a 200 day simple moving average of $68.77. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $80.86. The stock has a market capitalization of $248.10 billion, a P/E ratio of 39.23, a P/E/G ratio of 1.45 and a beta of 0.48. The company has a quick ratio of 0.70, a current ratio of 0.89 and a debt-to-equity ratio of 0.73.

AstraZeneca (NASDAQ:AZNGet Free Report) last announced its earnings results on Thursday, April 25th. The company reported $1.03 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.08. AstraZeneca had a return on equity of 30.42% and a net margin of 13.30%. The business had revenue of $12.68 billion during the quarter, compared to analysts’ expectations of $11.92 billion. On average, sell-side analysts expect that AstraZeneca PLC will post 4.04 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have weighed in on AZN. BMO Capital Markets increased their target price on AstraZeneca from $80.00 to $82.00 and gave the stock an “outperform” rating in a research report on Friday, April 26th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, April 16th. Argus increased their price target on AstraZeneca from $80.00 to $85.00 and gave the stock a “buy” rating in a research note on Thursday, May 30th. Finally, The Goldman Sachs Group initiated coverage on AstraZeneca in a research note on Thursday, May 30th. They issued a “buy” rating and a $97.00 price target for the company. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, AstraZeneca has a consensus rating of “Moderate Buy” and a consensus price target of $88.00.

Get Our Latest Analysis on AstraZeneca

About AstraZeneca

(Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Featured Stories

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZNFree Report).

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.